No headlines found.
Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update
Globe Newswire (Wed, 1-May 7:00 AM ET)
Globe Newswire (Wed, 24-Apr 7:00 AM ET)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 16-Apr 4:05 PM ET)
Chimerix Appoints Marc D. Kozin to Board of Directors
Globe Newswire (Thu, 21-Mar 7:00 AM ET)
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
Globe Newswire (Thu, 29-Feb 7:00 AM ET)
Chimerix to Present at TD Cowen 44th Annual Health Care Conference
Globe Newswire (Tue, 27-Feb 7:00 AM ET)
Globe Newswire (Thu, 22-Feb 7:00 AM ET)
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Chimerix trades on the NASDAQ stock market under the symbol CMRX.
As of May 14, 2024, CMRX stock price declined to $0.99 with 212,147 million shares trading.
CMRX has a beta of 0.97, meaning it tends to be less sensitive to market movements. CMRX has a correlation of 0.06 to the broad based SPY ETF.
CMRX has a market cap of $86.56 million. This is considered a Micro Cap stock.
Last quarter Chimerix reported $0 in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-50,000 and missed earnings estimates by -$.04.
In the last 3 years, CMRX stock traded as high as $9.29 and as low as $.88.
The top ETF exchange traded funds that CMRX belongs to (by Net Assets): VTI, VXF, IWC, GERM.
CMRX has underperformed the market in the last year with a return of -11.6%, while the SPY ETF gained +28.3%. In the last 3 month period, CMRX fell short of the market, returning -3.9%, while SPY returned +5.8%. However, in the most recent 2 weeks CMRX has outperformed the stock market by returning +5.9%, while SPY returned +2.2%.
CMRX support price is $1.01 and resistance is $1.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMRX stock will trade within this expected range on the day.